RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection risk during delivery of childhood vaccination campaigns: a modelling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.14.21257215
DO 10.1101/2021.05.14.21257215
A1 Simon R Procter
A1 Kaja Abbas
A1 Stefan Flasche
A1 Ulla Griffiths
A1 Brittany Hagedorn
A1 Kathleen M O’Reilly
A1 CMMID COVID-19 Working Group
A1 Mark Jit
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.14.21257215.abstract
AB Background The COVID-19 pandemic has disrupted delivery of immunisation services globally. Many countries have postponed vaccination campaigns out of concern about infection risks to staff delivering vaccination, the children being vaccinated and their families. The World Health Organization recommends considering both the benefit of preventive campaigns and the risk of SARS-CoV-2 transmission when making decisions about campaigns during COVID-19 outbreaks, but there has been little quantification of the risks.Methods We modelled excess SARS-CoV-2 infection risk to vaccinators, vaccinees and their caregivers resulting from vaccination campaigns delivered during a COVID-19 epidemic. Our model used population age-structure and contact patterns from three exemplar countries (Burkina Faso, Ethiopia, and Chile). It combined an existing compartmental transmission model of an underlying COVID-19 epidemic with a Reed-Frost model of SARS-CoV-2 infection risk to vaccinators and vaccinees. We explored how excess risk depends on key parameters governing SARS-CoV-2 transmissibility, and aspects of campaign delivery such as campaign duration, number of vaccinations, and effectiveness of personal protective equipment (PPE) and symptomatic screening.Results Infection risks differ considerably depending on the circumstances in which vaccination campaigns are conducted. A campaign conducted at the peak of a SARS-CoV-2 epidemic with high prevalence and without special infection mitigation measures could increase absolute infection risk by 32% to 58% for vaccinators, and 0.3% to 0.9% for vaccinees and caregivers. However, these risks could be reduced to 3.6% to 8.0% and 0.1% to 0.4% respectively by use of PPE that reduces transmission by 90% (as might be achieved with N95 respirators or high-quality surgical masks) and symptomatic screening.Conclusions SARS-CoV-2 infection risks to vaccinators, vaccinees and caregivers during vaccination campaigns can be greatly reduced by adequate PPE, symptomatic screening, and appropriate campaign timing. Our results support the use of adequate risk mitigation measures for vaccination campaigns held during SARS-CoV-2 epidemics, rather than cancelling them entirely.Competing Interest StatementBH was employed by the Bill and Melinda Gates Foundation while contributing to this study.Funding StatementThe following funding sources are acknowledged for providing funding for the named authors. This work was funded by the Bill & Melinda Gates Foundation (INV-016832: SRP, KA and MJ, OPP1191821: KMO). Wellcome Trust (208812/Z/17/Z: SF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data were from secondary sources in the public domain, and ethics approval was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalysis was performed using R version 4.0.2 and code is available online at: https://github.com/mert0248/vax_campaign_risk https://github.com/mert0248/vax_campaign_risk